araag2/HINT huggingface dataset:
Clinical trial NCT01227135 (phase 2, status: unknown status)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: hydroxychloroquine, imatinib mesylate
SMILES: CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic myeloid leukemia (CML) in chronic phase (CP)

          -  Has been treated with imatinib mesylate for at least 1 year

               -  Receiving a stable dose for ≥ 6 months prior to randomization

          -  Achieved at least major cytogenetic response (MCyR) and continues to be
             BCR/ABL-positive by quantitative polymerase chain reaction (Q-PCR)

          -  Must have a fusion gene present that can be monitored by Q-PCR

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,500/mm³ (stable and within normal range for ≥ 2 months)

          -  Platelet count ≥ 100,000/mm³ (stable and within normal range for ≥ 2 months)

          -  Serum albumin > 3 g/dL

          -  AST and/or ALT ≤ 2.5 times upper limit of normal (ULN)

          -  Serum bilirubin ≤ 1.5 times ULN

          -  Serum creatinine ≤ 1.5 times ULN OR 24-hour creatinine clearance ≥ 50 mL/min

          -  Serum potassium ≥ lower limit of normal with or without replacement therapy

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception (including a barrier
             method [i.e., condom]) during and for 3 months after completion of study therapy

          -  No impaired cardiac function, including any of the following:

               -  QTc > 450 msec on screening ECG

               -  Congenital long QT syndrome

               -  History or presence of sustained ventricular tachycardia

               -  History of ventricular fibrillation or Torsades de pointes

               -  NYHA class III-IV congestive heart failure

               -  Uncontrolled hypertension

          -  No severe gastrointestinal (GI) disorder, uncontrolled epilepsy, known
             glucose-6-phosphate dehydrogenase (G6PD) deficiency, known porphyria, moderate or
             severe psoriasis, known myasthenia gravis, or other concurrent severe and/or
             uncontrolled medical conditions

          -  No preexisting maculopathy of the eye

          -  No significant history of noncompliance to medical regimens or the inability to grant
             a reliable informed consent

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior chemotherapy, investigational drug, or major surgery and
             recovered

          -  More than 6 months since change in imatinib mesylate dose

          -  No other concurrent anticancer therapy or radiotherapy
Clinical trial NCT00519376 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: gw642444m, gw642444h, placebo
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Male or female (of non-childbearing potential) > or = 40 years

          -  History of COPD

          -  Smoker or ex-smoker

          -  Body weight > or = 50 kg with BMI 18-32 kg/m2

        Exclusion criteria:

          -  History of significant disease

          -  Subjects with a primary asthma diagnosis

          -  Alpha-1 antitrypsin deficiency as underlying cause of COPD

          -  Recent respiratory tract infection

          -  Poorly controlled COPD

          -  Blood potassium level < 3.5mmol/L

          -  Short-term or long tern oxygen therapy

          -  Recent participation in another trial

          -  History of drug or alcohol abuse

          -  Known allergies

          -  Recent blood donation

          -  ECG abnormalities
Clinical trial NCT00138151 (phase 2, status: terminated)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: isotretinoin, paclitaxel
SMILES: C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    slow accrual and lack of study drug
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically and/or cytologically confirmed cervical cancer, meeting 1 of the
             following criteria:

               -  Stage IVB disease

               -  Recurrent disease

               -  Persistent disease

          -  Patients previously treated with chemoradiotherapy as initial therapy must demonstrate
             disease progression

          -  Measurable disease by physical exam or radiographic studies

          -  Not amenable to chemoradiotherapy or surgery

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 6 months

        Hematopoietic

          -  WBC ≥ 3,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  SGOT and SGPT ≤ 2 times upper limit of normal

          -  Bilirubin ≤ 1.5 mg/dL

        Renal

          -  Creatinine ≤ 1.5 mg/dL OR

          -  Creatinine clearance ≥ 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known HIV positivity

          -  No active infection

          -  No medical condition that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior interferon

          -  No other concurrent immunotherapy

        Chemotherapy

          -  See Disease Characteristics

          -  At least 3 months since prior chemoradiotherapy (6 weeks for patients experiencing
             disease progression after completion of initial chemoradiotherapy)

          -  No other prior chemotherapy

        Endocrine therapy

          -  No concurrent hormonal therapy for cancer

        Radiotherapy

          -  See Disease Characteristics

          -  See Chemotherapy

          -  Recovered from prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Recovered from prior surgery

          -  No concurrent surgery for cancer

        Other

          -  No prior retinoids

          -  No other concurrent anticancer therapy

          -  No other concurrent experimental agents
Clinical trial NCT00555906 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, dexamethasone, pd 0332991
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of symptomatic multiple myeloma as defined by International Myeloma Working
             Group (IMWGURC).

          -  Phase 1: Relapsed or relapsed/refractory myeloma after at least 1 previous treatments
             and with a life expectancy of more than 3 months.

          -  Phase 2: Measurable (as defined by IMWGURC) disease after at least 1 previous
             treatment.

        Exclusion Criteria:

          -  History of allogeneic stem cell transplant.

          -  Phase 2 only: Prior bortezomib therapy will only be allowed if there was a
             demonstrated positive response, and disease progression occurred off therapy.

          -  Must have not experienced significant blood level changes, e.g. very low platelets,
             while on previous bortezomib therapy

          -  Prior radiation therapy to > 25% of the bone marrow (whole pelvis is 25%).
Clinical trial NCT00282087 (phase 2, status: completed)
Conditions: leiomyosarcoma, uterine neoplasm
ICD codes: C57.4, D28.2
Drugs: gemcitabine, docetaxel, doxorubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 years of age

          -  high risk uterine LMS, FIGO stage I or II

          -  pathology review of LMS high grade and /or mitotic rate greater than or equal to 5
             mitoses/10 hpf

          -  no longer than 12 weeks from surgical resection of cancer

          -  no evidence of residual disease

          -  ECOG 0 or 1

          -  ANC ≥ 1,500, hemoglobin ≥ 8.0, platelets ≥100,000

          -  creatinine ≤ 1.5 x institutional upper limits of normal

          -  adequate liver function

          -  neuropathy (sensory and motor) ≤ CTC grade 1

          -  negative pregnancy test

          -  signed consent

        Exclusion Criteria:

          -  patients with other invasive malignancies

          -  prior therapy with gemcitabine or docetaxel or doxorubicin

          -  hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80

          -  women who are breast feeding

          -  cardiac ejection fraction <50%

          -  prior pelvic irradiation

          -  treatment with hormone replacement or anti-hormonal agents or other cytotoxic agents
Clinical trial NCT01878864 (phase 2, status: terminated)
Conditions: pain and discomfort during scaling and root planning of patients with, periodontitis
ICD codes: K04.5, K05.20, K05.30, K05.211, K05.212, K05.213, K05.221
Drugs: bupivacaine lozenge, lidocaine-adrenalin injection
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    too slow patient inclusion and superior effect of the injection
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed as having, respectively periodontitis marginalis adulta progressiva
             lenta and periodontitis marginalis adulta progressiva rapid in the hygiene phase,
             where depurations are repeated within a short timeframe

          -  Age between 18 and 80 years

          -  Ability to speak, read and understand danish

          -  Ability to give oral and written consent

        Exclusion Criteria:

          -  Known allergy to bupivacaine or other local anaesthetics of the amide type

          -  Other gingival infections (eg lichen planus)

          -  Pregnancy -if in doubt a pregnancy test will be made

          -  Breastfeeding
Clinical trial NCT00475670 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab, taxane (docetaxel or paclitaxel)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  at least 10 months of Herceptin treatment for HER2-positive early breast cancer;

          -  metastatic breast cancer >=12 months after discontinuation of Herceptin;

          -  measurable disease.

        Exclusion Criteria:

          -  previous chemotherapy for metastatic breast cancer;

          -  brain metastases;

          -  invasive malignancy other than metastatic breast cancer.
Clinical trial NCT00067314 (phase 2, status: completed)
Conditions: breast neoplasms, neoplasm metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: edotecarin
SMILES: OCC(CO)NN1C(=O)C2=C3C(NC4=C3C=CC(O)=C4)=C3N([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C4=C(C=CC(O)=C4)C3=C2C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced or metastatic breast cancer not amenable to surgery or radiation with
             curative intent

          -  Must have received any chemotherapy regimen in the past

          -  Evidence of tumor resistance to last chemotherapy defined as progression after 6
             months of previous chemotherapy for advanced disease

          -  Must have measurable (by imaging techniques) disease

          -  Adequate bone marrow, liver and renal function

          -  Must provide evidence of informed consent and willingness and ability to comply with
             scheduled visits, treatment plan and study procedures.

        Exclusion Criteria:

          -  Received more than 2 prior chemotherapy regimens for metastatic disease

          -  Received in the past another drug of the same class as the investigational drug, i.e.
             topoisomerase I inhibitor

          -  Enrolled in another clinical intervention study

          -  Pregnancy, breast feeding, fertile women refusing to use reliable contraceptive
             methods

          -  Cardiac or thrombotic event in the last 12 months

          -  Brain metastases
Clinical trial NCT01161602 (phase 2, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: pumosetrag, pumosetrag, pumosetrag
SMILES: O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O, O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O, O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with history of Gastroesophageal Reflux Disease (GERD) symptoms (heartburn,
             regurgitation, acid taste in mouth).

          -  Between ages of 18 - 70 inclusive.

          -  Develop GERD symptoms following ingestion of a refluxogenic meal.

          -  Able to take a stable Proton Pump Inhibitor (PPI) regimen for duration of study.

          -  Understand and sign the informed consent form.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Allergic to pumosetrag or formulation excipients.
Clinical trial NCT00375219 (phase 2, status: completed)
Conditions: chronic myeloid leukemia
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: omacetaxine mepesuccinate
SMILES: [H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients, age 18 years or older

          -  Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic,
             accelerated, or blast phase

          -  The patient will have the T315I BCR-ABL gene mutation

          -  Patients will have failed prior imatinib therapy

          -  ECOG performance status 0-2

        Exclusion Criteria:

          -  NYHA class III or IV heart disease, active ischemia or any other uncontrolled cardiac
             condition such as angina pectoris, clinically significant cardiac arrhythmia and
             requiring therapy, uncontrolled hypertension or congestive heart failure

          -  Myocardial infarction in the previous 12 weeks

          -  Lymphoid Ph+ blast crisis
Clinical trial NCT00355524 (phase 2, status: completed)
Conditions: hiv-1, hiv infections
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, Z21
Drugs: tmc114, ritonavir
SMILES: [H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with documented human immunodeficiency virus (HIV)-1 infection failing
             their current antiretroviral therapy

          -  Body weight for Part 1: greater than or equal to 20 Kilogram (kg) but less than 50 kg
             and body weight for Part 2: greater than or equal to 50 kg and from greater than or
             equal to 20 but less than 50 kg after pediatric dose selection

          -  Able to swallow the TMC114 tablet formulations, the ritonavir capsule formulation, and
             to tolerate the ritonavir liquid formulation

          -  Stable cluster of differentiation 4 (CD4+) percentage; that is no more than 5 percent
             decrease in CD4+ percentage between the Screening visit and the last available CD4+
             measurement

          -  Female participants who are sexually active and able to become pregnant must use a
             safe and effective birth control method

        Exclusion Criteria:

          -  For Part 1: Use of the non-nucleoside analogue reverse transcriptase inhibitor (NNRTI)
             efavirenz as part of the current regimen was not allowed and for Part 2: Use of
             efavirenz as part of the current regimen was allowed and use of any antiretroviral and
             non-antiretroviral investigational agents within 30 days prior to screening

          -  Presence of any currently active acquired immune deficiency syndrome (AIDS) defining
             illness (Category C conditions according to the Centers for Disease Control [CDC]
             Classification System for HIV Infection 1993 or according to the 1994 revised CDC
             Classification System for HIV infection in children less than 13 years of age)

          -  Pregnant or breastfeeding female participants

          -  Previous allergy or hypersensitivity to any excipients of the investigational
             medication (TMC114) or ritonavir

          -  Any Grade 3 or 4 toxicity as defined by the Division of Acquired Immunodeficiency
             Syndrome (DAIDS) grading scale
Clinical trial NCT01458340 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder, adhd
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: td-9855, td-9855, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must meet the following ADHD diagnostic and inclusion criteria:

          -  Subjects must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, Text Revision (DSM-IV-TR) criteria for current ADHD subtypes (ADHD combined
             type, ADHD predominately inattentive type, ADHD predominately hyperactive-impulsive
             type) as assessed by the clinical interview and confirmed by Adult
             Attention-Deficit/Hyperactivity Disorder Clinical Diagnostic Scale (ACDS V1.2).

          -  Subjects must have a total score of 24 or greater on the AISRS at both the Screening
             and Baseline Visits AND the Baseline Visit AISRS scores must not vary by more than 20%
             from Screening.

          -  Subjects are required to have CGI-S score ≥4 (moderate) at both the Screening and
             Baseline Visits. Subjects should have at least moderate severity for ADHD symptoms.

          -  For women of childbearing potential, documentation of a negative serum pregnancy test
             at Screening and a negative urine pregnancy test on Day 0. All female subjects of
             childbearing potential must be using a highly effective method of birth control during
             the study and for at least 1 month after completion of study drug dosing.

          -  A highly effective method of birth control is defined as one that results in a low
             failure rate (i.e., <1% per year) when used consistently and correctly, such as condom
             + diaphragm, condom + spermicide, diaphragm + spermicide, or intrauterine device [IUD]
             with documented failure rate of <1% per year, or oral/injectable/implanted hormonal
             contraceptives used in combination with a barrier method.

          -  Women are considered to be not of childbearing potential if they have had a total
             hysterectomy or bilateral tubal ligation (documentation for either must be provided
             before enrollment) or are at least 2 years postmenopausal. Female subjects cannot be
             breast-feeding.

        Exclusion Criteria:

        Any current psychiatric disorder other than ADHD as defined in DSM-IV-TR as assessed by
        Mini International Neuropsychiatric Interview (MINI). Subjects with dysthymia that does not
        require pharmacological treatment will not be excluded.

          -  MADRS total score >15.

          -  A diagnosis of ADHD NOS.

          -  Any diagnosis of lifetime bipolar disorder or psychotic disorder

          -  A current diagnosis of any severe comorbid Axis II disorder

          -  Any history of mental retardation, organic mental disorders due to general medical
             condition or pervasive developmental disorder as defined by DSM-IV-TR.-
Clinical trial NCT01108393 (phase 2, status: completed)
Conditions: obsessive compulsive disorder
ICD codes: F42.8, F42.9, F60.5
Drugs: agomelatine a, placebo
SMILES: COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Obsessive Compulsive Disorder (OCD) according to Diagnostic and Statistical Manual,
             Fourth Edition, Text Revision (DSM-IV-TR),

          -  Y-BOCS total score ≥ 20,

          -  duration of OCD symptoms of at least one year.

        Exclusion Criteria:

          -  Bipolar disorder, Schizophrenic or Psychotic Disorder

          -  Severe or uncontrolled organic diseases

          -  Neurological disorder

          -  Women of childbearing potential who are not using effective contraception
Clinical trial NCT00396591 (phase 2, status: completed)
Conditions: ovarian neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Participants that met the following criteria were eligible.

        Inclusion Criteria:

          -  Symptomatic malignant ascites resulting from advanced ovarian epithelial cancer
             (including fallopian tube and primary peritoneal adenocarcinoma) that required at
             least 3 previous therapeutic paracenteses at a frequency of 1 to 4 paracenteses per
             month for management.

          -  Platinum resistant disease defined by relapse or progression of disease during or
             after treatment, or drug intolerance.

          -  Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or
             progression of disease during or after treatment, or drug intolerance.

        Exclusion Criteria:

          -  Peritoneovenous or other type of shunt that was placed for the management of ascites

          -  Prior treatment with a VEGF or VEGF receptor inhibitor

          -  Uncontrolled hypertension

        The above information is not intended to contain all considerations relevant to
        participation in a clinical trial.